Overview

* Aptar Q2 sales rise 6% yr/yr to $966 mln, beating analyst expectations

* Adjusted EPS for Q2 beats consensus, rising 18% to $1.66

* Co returns $100 mln to shareholders via dividends and share repurchases

Outlook

* Aptar expects Q3 EPS between $1.53 and $1.61

* Aptar sees challenges from normalizing naloxone sales

* Company expects modest Q3 contributions from Closures and Beauty

Result Drivers

* PHARMA SEGMENT - Strong demand in Prescription, Injectables, and Active Material Science divisions drove sales growth

* BEAUTY SEGMENT - Growth in personal care products offset by lower demand in beauty dispensing technologies due to tariff uncertainties

* CLOSURES SEGMENT - Increased demand in food and beverage markets across regions and applications fueled sales growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $966 mln $956 mln

(5

Analysts

)

Q2 Beat $1.66 $1.56 (6

Adjusted Analysts

EPS )

Q2 EPS $1.67

Q2 Net $112 mln

Income

Q2 Beat $218 mln $210.50

Adjusted mln (5

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

* Wall Street's median 12-month price target for Aptargroup Inc ( ATR ) is $175.00, about 10.2% above its July 31 closing price of $157.14

* The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 26 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)